Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2006 studies found for:    melanoma
Show Display Options
Rank Status Study
21 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
22 Unknown  Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
23 Recruiting Prospective Melanoma Database
Condition: Melanoma
Intervention: Other: clinical biological data collection on melanoma
24 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: QS21;   Biological: IFA (incomplete Freund's adjuvant);   Biological: p946;   Biological: p946/tet-p;   Biological: Tet-p
25 Active, not recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
26 Recruiting Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Conditions: Melanoma;   Oligometastatic Melanoma
Interventions: Drug: Nivolumab 1mg/kg;   Drug: Ipilimumab;   Drug: Nivolumab 3 mg/kg
27 Completed
Has Results
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin;   Biological: gp100 antigen;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine;   Biological: tyrosinase peptide
28 Terminated Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: medical chart review
29 Recruiting Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Condition: Metastatic Melanoma to the Groin Lymph Nodes
Interventions: Procedure: Inguinal Lymphadenectomy;   Procedure: Ilio-inguinal Lymphadenectomy
30 Recruiting Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
Condition: Metastatic Melanoma
Intervention: Other: patients with metastatic melanoma
31 Active, not recruiting A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma
Condition: High Risk Melanoma
Interventions: Drug: Ipilumimab;   Radiation: Radiation
32 Unknown  A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
Conditions: Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma
Intervention: Biological: CB-10-01 (Transgenic Lymphocyte Immunization)
33 Not yet recruiting Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Pembrolizumab
34 Completed Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma
Condition: Melanoma
Intervention: Other: Sampling of blood
35 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
36 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
37 Completed Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
38 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
39 Recruiting Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
Conditions: Melanoma;   Brain Metastases
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
40 Completed Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
Condition: Melanoma
Interventions: Biological: Autologous, DNP-modified vaccine (M-Vax);   Biological: Autologous, DNP-Modified Melanoma Vaccine;   Biological: Autologous, DNP-Modified Vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years